Press release centre
Past Press Releases - Alizé Pharma
March 2, 2015
Alizé Pharma launches Phase II clinical trial of AZP-531 in Prader-Willi syndrome
Alizé Pharma, a company specialized in the development of drugs for the treatment of metabolic disorders and rare diseases, today announces the launch of a Phase II clinical trial of AZP-531, its unacylated ghrelin analog, in patients with Prader-Willi syndrome. More
September 10, 2014
Alize Pharma raises EUR 5 million (USD 6.6 million) from Bpifrance/InnoBio and its existing share...
The proceeds will finance the clinical development program of AZP531 (an unacylated ghrelin analog) in Prader-Willi syndrome and type 2 diabetes. More
December 3, 2009
Alizé Pharma reveals promising data on Asparec program for second-line ALL therapy
Metabolic disease and cancer specialist will present preclinical data on therapy for acute lymphoblastic leukemia (ALL) at the American Society of Hematology, New Orleans, Louisiana, December 6, 2009. More | | Data
27,633
Tech investments
From our Online Data Service
|
17,827
VC-backed companies
From our Radar
|
Recent Deals
For information on Europe's most extensive database on technology funding click here!
|  |
Events
Press Releases
|
